Comparing the Efficacy of Hybrid, High-dose Dual and Bismuth Quadruple Therapies

Bismuth quadruple therapy has been recommended as a choice of the first‐line treatment for H. pylori infection in several important international consensuses. However, it is associated with a high frequency of adverse events. Both hybrid and high‐dose dual therapies developed by the scholars from Taiwan can achieve a high eradication rate for clarithromycin‐resistant strains, and have a great potential to replace bismuth quadruple therapy in the treatment of H. pylori infection. In the second‐line treatment, tetracycline‐levofloxacin quadruple therapy developed by our study group can achieve a higher eradication rate than levofloxacin triple therapy for salvage treatment of hybrid therapy. However, whether the new therapy can be a promising rescue treatment for bismuth quadruple or high‐dose dual therapy remains unanswered.